How pharmaceutical leaders are operationalizing AI
Pharmaceutical companies are embedding AI into core workflows to accelerate drug discovery, manufacturing, and supply chain operations while maintaining compliance and human oversight.
Bringing a new therapy to market remains one of the most challenging endeavors in healthcare, with drug development often taking over a decade and billions of dollars before reaching patients. Pharmaceutical organizations face pressure to accelerate research, improve manufacturing, and enhance supply chain resilience while delivering personalized patient experiences. AI is increasingly embedded in core scientific, manufacturing, operational, and commercial workflows, shifting from experimentation to enterprise-wide adoption. Leaders are now focused on scaling AI to bring therapies to patients faster, operate more efficiently, and improve health outcomes.
AI’s immediate value in research and development is expanding the number, speed, and quality of decisions researchers can evaluate while keeping scientific expertise central. Microsoft’s Discovery platform connects scientific knowledge, data, and tools into an evidence-driven process, enabling faster hypothesis testing and institutional knowledge access. Novo Nordisk’s AI reasoning agent reduced time-to-insight from weeks to minutes and increased evaluation capacity from 5-10 to over 50 ideas per quarter, while Amgen’s Catalyst Copilot shortened discovery cycles by making institutional knowledge searchable via natural language.
AI is also transforming pharmaceutical manufacturing by modernizing production processes, improving productivity, and maintaining compliance in regulated environments. Körber’s platform, powered by Azure OpenAI and Foundry, reduced recipe-management timelines from months to hours and cut manual work by up to 40% in pilot implementations. PharmaGuardrails demonstrated near 99% precision for pharmaceutical tasks and 100% numerical precision for production-critical values, enabling trusted AI-assisted workflows on the shop floor.
Supply chain resilience is becoming a critical focus as organizations modernize platforms to unify operational data and improve agility. Rohto Pharmaceutical reduced manual data-entry time by 50% and established a standardized global operating model for future AI-powered planning. Astellas migrated 500 terabytes of data across 250 servers, closed six global datacenters, and completed the process in six months to support scalable innovation and operational agility.